Clinical and laboratory COVID-19 features in hospitalized patients with concomitant diabetes mellitus type 2: A retrospective study

Arailym Abilbayeva 1 * , Anel Tarabayeva 1, Gulzhana Idrisova 1, Aigul Abdrakhmanova 2, Ainur Sadykova 3, Ravilya Yegemberdiyeva 3, Amangul Duisenova 3
More Detail
1 Department of General Immunology, Asfendiyarov Kazakh National Medical University, Almaty Kazakhstan
2 City Clinical Infectious Diseases Hospital named after I.Zhekenova, Almaty, Kazakhstan
3 Department of Infectious and Tropical Diseases, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 19, Issue 6, pp. 83-88.
OPEN ACCESS 762 Views 577 Downloads
Download Full Text (PDF)


Objective: To investigate the prevalence of diabetes mellitus in comorbidity structures and its effect on the clinical course in hospitalized COVID-19 patients in south region of Kazakhstan.
Material and methods: A retrospective analysis of data from 918 patients with COVID-19 treated at the City Clinical Infectious Diseases Hospital was carried out. Pearson's Chi-square test and Student's t-test were conducted.
Results: In Kazakhstan, diabetes mellitus occupies the second position in the structure of comorbidities in patients with COVID-19 with a share of 20%. Diabetes mellitus in patients most often occurs in combination with cardiovascular diseases and arterial hypertension (20.3% and 16.3%, respectively). Combination of diabetes mellitus, arterial hypertension and other diseases was detected in 72.4% of patients. Combination of diabetes mellitus, cardiovascular and other diseases was detected in 32.5%.
In diabetes mellitus patients, COVID-19 was more severe, the hospital stay was longer, and patients over 60 years of age suffered. These patients had a combination of diabetes mellitus with arterial hypertension, obesity, and cardiovascular diseases. Hyperglycemia, elevated blood pressure, rapid breathing, and low saturation were more common for these patients.
Conclusion: Diabetes mellitus ranks second in the structure of comorbidities in COVID-19 in the south region of Kazakhstan and is characterized by a combination with cardiovascular diseases, arterial hypertension and obesity. In patients with diabetes, COVID-19 is more severe, which affects the length of stay in the hospital, the mortality rate and the need for transfer to the Intensive Care Unit.


Abilbayeva A, Tarabayeva A, Idrisova G, Abdrakhmanova A, Sadykova A, Yegemberdiyeva R, et al. Clinical and laboratory COVID-19 features in hospitalized patients with concomitant diabetes mellitus type 2: A retrospective study. J CLIN MED KAZ. 2022;19(6):83-8.


  • WHO WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020.URL: (date of the application: 01.09.2022)
  • OUR world in data. URL: (date of the application: 01.09.2022)
  • Zhalmagambetov B., Madikenova M., Paizullayeva S., Abbay A., Gaipov A. COVID-19 Outbreak in Kazakhstan: Current Status and Challenges. JCMK. 2020;1(55):6-8.
  • Gaipov A., Gusmanov A., Abbay A., Sakko Y., Issanov A. et al. SARS-CoV-2 PCR-positive and PCR-negative cases of pneumonia admitted to the hospital during the peak of COVID-19 pandemic: analysis of in-hospital and post-hospital mortality. BMC Infectious Diseases. 2021; 21:458.
  • Baradaran A., Ebrahimzadeh M.H., Baradaran A., Kachooei A.R. Prevalence of Comorbidities in COVID-19 Patients: A systematic review and meta-analysis.Arch Bone Jt Surg. 2020;8:247-255.
  • Thakur B., Dubey P., Benitez J., Torres J.P., Reddy S. et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19.Scientific Reports. 2021;11:1-13.
  • Pya Y., Bekbossynova M., Gaipov A., Lesbekov T., Kapyshev T. et al. Mortality predictors of hospitalized patients with COVID-19: Retrospective cohort study from Nur-Sultan, Kazakhstan. PLOSONE. 2021.
  • Nandy K., Salunke A., Pathak S.K., Pandey A. et al. Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events.Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020; 14(5):1017-1025.
  • Unnikrishnan R., Misra A. Diabetes and COVID19: a bidirectional relationship. Nutr Diabetes.2021;11(1):21-26.
  • Varikasuvu S.R., Dutt N., Thangappazham B., Varshney S. Diabetes and COVID-19: A pooled analysis related to disease severity and mortality.Prim Care Diabetes. 2021;15 (1):24-27.
  • Cyril P.L., Eelco J.P.K. COVID-19 and diabetes: understanding the interrelationship and risks for a severe course. Front Endocrinol (Lausanne). 2021;12:e649525.
  • "Republican Center for Electronic Health". (Date of the application – 10.11.2022)
  • Pranata R., Lim M.A., Huang I., Raharjo S.B., Lukito A.A. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020; 21(2):e1470320320926899.
  • Mubarik S., Liu X., Eshak E.S., Liu K. et al. The sssociation of hypertension with the severity of and mortality from the COVID-19 in the early stage of the epidemic in Wuhan, China: A multicenter retrospective cohort study.Frontiers in medicine. 2021;8: e623608.
  • Raymond P., Huang I., Lim M.A., Wahjoepramono E.J., July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19–systematic review, meta-analysis, and meta-regression. Journal of Stroke and CerebrovascularDiseases. 2020;29(8):e104949.
  • Demeulemeester F., Punder K., Heijningen M., Doesburg F. Obesity as a risk factor for severe COVID-19 and complications: a review. Cells. 2021;10(4):933.
  • Sattar N., McInnes I.B., McMurray J.J.V. Obesity is a risk factor for severe COVID-19 Infection. Circulation. 2020;142(1):4-6.
  • Makhoul E., Aklinski J.L., Miller J., Leonard C. et al. A review of COVID-19 in relation to metabolic syndrome: obesity, hypertension, diabetes, and dyslipidemia. Cureus. 2022;14(7):e27438.
  • Wu S., Zhou K., Misra-Hebert A., Bena J., Kashyap S.R. Impact of metabolic syndrome on severity of COVID-19 illness. Metab Syndr Relat Disord. 2022;20(4):191-198.
  • Zhou Y., Chi J., Lv W., Wang Y. Obesity and diabetes as high‐risk factors for severe coronavirus disease 2019 (Covid‐19). Diabetes Metab Res Rev. 2021;37(2):e3377.
  • Shi Q., Zhang X., Jiang F., Zhang X. et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: A two-center, retrospective study. Diabetes Care. 2020;43(7):1382–1391.
  • Conway J., Gould A., Westley R., Raju S.A. et al. Characteristics of patients with diabetes hospitalised for COVID-19 infection-a brief case series report. Diabetes Research and Clinical Practice. 2020;169:e108460.
  • Angelidi A.M., Belanger M.J., Mantzoros C.S. COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next. Metab Clin Exp. 2020;107:e154245.
  • Kumar A., Arora A., Sharma P., Anikhindi S.A. et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr. 2020;14(4):535–545.
  • Kulcsar K.A., Coleman C.M., Beck S.E., Frieman M.B. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight. 2019;4(20):e131774.
  • Wang A., Zhao W., Xu Z., Gu J. Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Res Clin Pract. 2020;162:e108118.
  • Michalakis K., Ilias I. SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects. Diabetes Metab Syndr. 2020;14(4):469-471.
  • Albulescu R., Dima S.O., Florea I.R., Lixandru D. et al. COVID‑19 and diabetes mellitus: Unraveling the hypotheses that worsen the prognosis (Review). Experimental and Therapeutic Medicine. 2020;20(6):194.
  • Strain W.D., Hope S.V., Green A. et al. Type 2 diabetes mellitus in older people: a brief statement of key principles of modern day management including the assessment of frailty. A national collaborative stakeholder initiative. Diabet Med. 2018;35(7):838-845.
  • Muniyappa R., Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;318:E736–E741.
  • Hussain A., Bhowmik B., Moreira N.C.V. COVID-19 and diabetes: Knowledge in progress. Diabetes Research and Clinical Practice. 2020;162:e108142.